RXRX — Recursion Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.00bn
- $1.52bn
- $58.84m
Annual income statement for Recursion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.96 | 10.2 | 39.8 | 44.6 | 58.8 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -8.43 | 1.99 | 13.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 89.5 | 194 | 286 | 395 | 538 |
| Operating Profit | -85.5 | -184 | -246 | -350 | -479 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -87 | -186 | -239 | -332 | -465 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -87 | -186 | -239 | -328 | -464 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -87 | -186 | -239 | -328 | -464 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -87 | -186 | -239 | -328 | -464 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.531 | -1.48 | -1.36 | -1.57 | -1.69 |
| Dividends per Share |